1.1Capture with a DNA aptamer
A single-stranded DNA aptamer folds into stems and loops that form an antigen-binding surface. A terminal amine couples the aptamer to a carboxylated bead for capture of recombinant antigen from solution.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A single-stranded DNA aptamer folds into stems and loops that form an antigen-binding surface. A terminal amine couples the aptamer to a carboxylated bead for capture of recombinant antigen from solution.
An amide bond between the peptide termini closes the backbone into a ring. The ring constrains the side chains that contact the antigen, and a pendant spacer couples the peptide to a solid support.
A thin polymer film forms around a recombinant antigen fragment used as a template. Washing removes the template and exposes cavities with complementary shape and chemical groups that retain the fragment during an assay.
Stacked ankyrin repeats expose amino acid side chains along a concave surface that contacts the antigen. A terminal attachment tag anchors the protein to a sensor surface and leaves the contact surface exposed to the sample.
A beta barrel supports exposed loops around one opening. Side chains on those loops contact the antigen, and a terminal fluorescent label reports retention of the scaffold in a plate assay.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A cold-chain quality control station uses the binding agent as a test reagent in a plate assay. A plate coated with a noninfectious reference antigen receives aliquots from the stored lot and a retained reference lot, with buffer-only wells for background measurement. A labeled secondary reagent reports retained binding, and the station records the background-corrected signal ratio alongside the shipment temperature record.
An existing single-domain binding reagent containing the specified HCDR3 replaces the reagent based on an immunoglobulin heavy-chain variable region in an optical sensor cartridge. The sensor presents a noninfectious reference antigen on one channel and a matched antigen-free surface on a second channel. The same reagent solution passes over both surfaces, and subtraction of the second channel corrects for bulk optical shifts.
A 384-well plate carries a noninfectious reference antigen in the test wells and a blocking layer alone in the background wells. The plate receives 20 microliters per well at four binding-reagent dilutions spaced twofold, with three replicate wells per dilution. The reagent incubates for 30 minutes before the plate is washed and a fluorescent secondary reagent reports retained binding.
Two fluorescently distinguishable bead populations carry a noninfectious reference antigen and a control coating, respectively. The bead populations share one tube with the binding agent and are washed before receiving a fluorescent secondary reagent that recognizes the assay reagent. A flow cytometer identifies each bead population by its internal fluorescence and reports the difference in median reporter signal between the populations.
A chromatography fraction collector dispenses split aliquots from a binding-reagent purification run into a measurement plate. The measurement plate presents a noninfectious reference antigen, and a labeled secondary reagent reports binding in each aliquot. The fraction number links the plate signal to the corresponding chromatogram so the operator can identify fractions that contain functional binding reagent.
An autosampler delivers the binding agent and a retained reference lot to paired optical sensor channels containing a noninfectious reference antigen and a matched blank surface. Software subtracts the blank trace and averages the corrected signal over the last 10 seconds of the association phase. The software records the test-to-reference signal ratio with the reagent lot identifier and flags runs that exceed the configured blank drift limit.
A recombinant single domain variable region contains SEQ ID NO 18 in its third complementarity determining loop. The domain forms a compact beta sandwich and presents the loop on its antigen-binding face.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In particular, the present invention provides an antibody which comprises at least one heavy chain variable region (VH) that comprises three CDRs, wherein said heavy chain variable region comprises: (i) a heavy chain CDR1 domain that comprises the amino acid sequence SYSMN (SEQ ID NO. 35), (ii) a heavy chain CDR2 domain that comprises the amino acid sequence SISSSSSYIYYADSVKG (SEQ ID NO. 39), and (iii) a heavy chain CDR3 domain that comprises the amino acid sequence SSGWYDGEFA · US 2008/0085241 A1 · abstract
Overall, as is well known for immunoglobulin variable domains generally, the ISVD's invention will comprise 4 framework regions (FW1, FW2. FW3 and FW4) and 3 CDR's (CDR1, CDR2 and CDR3).B · US 11,009,511 B2 · ¶ 41
An empty cell means only that no passage was reproduced there.
Those selected statistics and facts however, illustrate well the need for cancer treatments with better safety and efficacy profiles.A · US 2008/0085241 A1 · ¶ 6
One of the causes for the inadequacy of current cancer treatments is their lack of selectivity for affected tissues and cells.A · US 2008/0085241 A1 · ¶ 7
The present invention relates to methods, assays and techniques for detecting and/or measuring anti-drug antibodies (ADA's), and in particular treatment-emergent ADA's.B · US 11,009,511 B2 · ¶ 2
As further described herein, the methods, assays and techniques of the invention can in particular be used for detecting and/or measuring ADA's in a sample (such as a blood sample or another biological sample as mentioned herein) that has been obtained from a (human) subject to whom such a protein, polypeptide, compound or molecule has been administered.B · US 11,009,511 B2 · ¶ 6
patent.fyi, US 2026/0356921 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356921/, SHA-256 4864efe36823eeb61cc83180a709528399b2fb29efa50d2f82e2365af5243a81